GNS, a pioneer in using “Digital Twins” and causal AI to find and create novel medications, announced today that it is changing its name to Aitia (pronounced “ay-tee-ah”). Aitia, whose name is taken from the Greek term for causation, will concentrate on using its Gemini Digital Twins even more to find the following wave of ground-breaking medicines to enhance patient outcomes. In multiple myeloma, prostate cancer, Alzheimer’s, Parkinson’s, and Huntington’s disease as well as other diseases involving oncology, neurodegeneration, and immunology, Gemini Digital Twins are being utilised to find new treatments and speed up R&D.
From the very beginning of the discovery phase all the way to pre-IND, Aitia will collaborate with biopharma businesses. In order to replicate their treatment prospects in patient cohorts drawn from the Gemini Digital Twins, Aitia will also keep working with top biopharma companies.
Colin Hill, CEO and co-founder of Aitia, stated that “we are taking this crucial step in our evolution to capitalise on the amazing discoveries that are emerging from our Digital Twins.” “Because of the strength of the causal AI technology we utilised to build the Digital Twins and the accessibility of extensive multi-omic patient data, these discoveries are now occurring at an accelerated rate. In order to push our discoveries through the drug discovery process and eventually see these discoveries reach the clinic and patients, we are eager to continue working with both our present partners and new partners.”
About AitiaAitia is a pioneer in the use of digital twins and causal AI to find the next wave of transformative medicines. Aitia is developing Digital Twins of illness in the fields of oncology, immunology, and neurological diseases by utilising the convergence of multi-omic patient data, high-performance computing, causal learning, and AI. Gemini Digital Twins are currently being utilised to find new treatments and speed up R&D for diseases like multiple myeloma, prostate cancer, Alzheimer’s, Parkinson’s, and Huntington’s, with several others in the works. Seven of the top ten pharmaceutical corporations, major academic medical facilities, leading medical societies, top multi-omic data providers, and patient advocacy organisations are among Aitia’s partners.
